🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

38 results for “ophthalmic” Clear

  1. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Conjunctivitis, Allergic

    phase 2 small molecule completed

    1 trial

  2. Voclosporin Ophthalmic Solution

    Aurinia Pharmaceuticals

    Dry Eye

    phase 2 small molecule completed

    1 trial

  3. A single and multiple ascending dose study of topical ladarixin ophthalmic solution in healthy volunteers

    Dompe' Farmaceutici S.p.A.

    Ocular inflammatory conditions

    phase 1 other active

    1 trial

  4. An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients

    AstraZeneca AB

    Breast Cancer

    phase 1 other active

    1 trial

  5. Bimatoprost Ophthalmic Solution, 0.01%

    Amneal Pharma Europe Ltd

    Open-angle Glaucoma

    phase 1 small molecule active

    1 trial

  6. LNZ101 (Aceclidine /Brimonidine) ophthalmic solution

    LENZ Therapeutics

    Presbyopia

    phase 1 small molecule completed

    1 trial

  7. TP-03 (Lotilaner Ophthalmic Solution), 0.25%

    Tarsus Pharmaceuticals

    Healthy

    phase 1 small molecule completed

    1 trial

  8. USB005 (aclerastide) Ophthalmic Solution

    United Therapeutics Europe Ltd

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  9. 0.1% bromfenac

    Zhongshan Ophthalmic Center, Sun Yat-sen University

    Pterygium

    approved small molecule completed

    1 trial

  10. Aflibercept Ophthalmic

    Regeneron UK Limited

    Wet Macular Degeneration

    approved small molecule completed

    1 trial

  11. Lotilaner ophthalmic solution, 0.25%

    Tarsus Pharmaceuticals

    Demodex Blepharitis

    approved small molecule completed

    1 trial

  12. Rebamipide 2% ophthalmic solution

    Samsung Bioepis NL B.V.

    Dry Eye Disease (DED)

    approved small molecule active

    1 trial

  13. 0.1% bromfenac ophthalmic solution

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cataract

    small molecule completed

    1 trial

  14. Routine IOP-lowering medications

    Zhongshan Ophthalmic Center, Sun Yat-sen University

    Open Angle Glaucoma

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources